Eli Lilly
Discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $6.5b | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 15 % | 1 % | 20 % | 32 % | 32 % | 20 % | 17 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 31 % | 33 % | 37 % | 43 % | 44 % | 48 % | 49 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 20 % | 22 % | 15 % | 24 % | 32 % | 35 % | 37 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 25 % | 25 % | 27 % | 24 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Eli Lilly and Company, commonly known as Lilly, is a global pharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that improve lives. Founded over 140 years ago, Lilly has a rich history of scientific breakthroughs, including the development of the first life-saving treatment for diabetes, insulin. The company operates in the healthcare and pharmaceutical market, focusing on creating treatments for various medical conditions.
Lilly serves a diverse range of clients, including healthcare professionals, hospitals, clinics, and patients worldwide. The company’s business model revolves around extensive research and development (R&D) to create new medicines, followed by manufacturing and distributing these products globally. Lilly invests heavily in R&D to discover new treatments and improve existing ones, ensuring they meet the highest standards of safety and efficacy.
The company makes money primarily through the sale of its prescription medicines. These products are sold to healthcare providers, who then prescribe them to patients. Lilly’s portfolio includes treatments for diabetes, cancer, immunology, pain management, and other serious health conditions. Additionally, Lilly collaborates with various partners, including Team USA, to promote health and wellness initiatives.
Lilly is also vigilant about protecting its products from counterfeiting and ensuring the availability of its medicines, such as tirzepatide and dulaglutide, which are crucial for managing diabetes. The company emphasizes its commitment to ethical practices, stating that it never asks for money in exchange for employment or investment opportunities.
In summary, Lilly is a leading pharmaceutical company dedicated to making life better through innovative medical solutions, serving a global market with a focus on quality and ethical standards.
Keywords: pharmaceutical, diabetes, insulin, R&D, healthcare, prescription medicines, innovation, global, ethical, treatments.
Tech stack
